References
- Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81
- Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 2004;18:177-83
- Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81:129-34
- Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain: Part I - assessment. P&T 2005;30:296-301
- Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain: Part II - management. P&T 2005;30:354-61
- Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharmaceut Sci 1998;1:15-30
- Instanyl® SPC. Nycomed UK Ltd. Date of revision: July 2009
- Actiq® SPC. Flynn Pharma Ltd, Republic of Ireland. Date of revision: October 2010
- Abstral® Sublingual Tablets SPC. ProStrakan Group Ltd, UK. Date of revision: February 2010
- Effentora® SPC. Cephalon Ltd, UK. Date of revision: January 2010
- Nalamachu S, Hassman D, Wallace MS, et al. Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain. Curr Med Res Opin 2011;27:519-30
- Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 2009;25:2877-85
- Dillmann U, Nilges P, Saile H, et al. Assessing disability in chronic pain patients. Schmerz 1994;8:100-10
- Herrmann C, Scholz KH, Kreuzer H. Psychologic screening of patients of a cardiologic acute care clinic with the German version of the Hospital Anxiety and Depression Scale. Psychother Psychosom Med Psychol 1991;41:83-92
- Farrar JT, Berlin JA, Strom BL. Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manage 2003;25:406-11
- Tait RC, Pollard CA, Margolis RB, et al. The Pain Disability Index: psychometric and validity data. Arch Phys Med Rehabil 1987;68:438-41
- Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70
- Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19
- Zeppetella G. Impact and management of breakthrough pain in cancer. Curr Opin Support Palliat Care 2009;3:1-6
- Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996;32A:1135-41
- Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001;91:123-30
- Portenoy RK, Taylor D, Messina J, et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006;22:805-11